MNG988
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.601
- G2M_CHECKPOINT+0.589
- MYC_TARGETS_V2+0.504
- TNFA_SIGNALING_VIA_NFKB+0.446
- INTERFERON_ALPHA_RESPONSE+0.435
- MYC_TARGETS_V1+0.435
- MTORC1_SIGNALING+0.430
- GLYCOLYSIS+0.399
- UNFOLDED_PROTEIN_RESPONSE+0.398
- INFLAMMATORY_RESPONSE+0.391
Top 10 suppressed
- HEME_METABOLISM-0.286
- APICAL_SURFACE-0.280
- TGF_BETA_SIGNALING-0.257
- WNT_BETA_CATENIN_SIGNALING-0.238
- MYOGENESIS-0.228
- BILE_ACID_METABOLISM-0.197
- COAGULATION-0.197
- APICAL_JUNCTION-0.196
- UV_RESPONSE_DN-0.186
- FATTY_ACID_METABOLISM-0.185
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518265 | — | E | 0.825 |
| 2 | TCGA-CV-7434-01A-11R-2132-07 | — | — | 0.824 |
| 3 | DRR168607 | — | — | 0.823 |
| 4 | TCGA-IQ-A61E-01A-22R-A30B-07 | — | — | 0.823 |
| 5 | fca4c327-dfab-4455-84a8-f890a7326132 | — | — | 0.816 |
| 6 | D1729A17-148B-4C58-BEB5-7C4349A0E920 | — | — | 0.808 |
| 7 | SRR6013600 | — | cohortA1 | 0.807 |
| 8 | MNG151 | — | — | 0.805 |
| 9 | TCGA-D8-A1XK-01A-21R-A14M-07 | — | E | 0.804 |
| 10 | c96595aa-4604-4ec6-8b54-c97b3543777e | — | — | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.601 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.589 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.504 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.446 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.435 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.435 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.430 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.399 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.398 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.391 | Idelalisib | — uncovered |
| HYPOXIA | 0.367 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.305 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.304 | Inavolisib | — uncovered |
| APOPTOSIS | 0.268 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.268 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.248 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.236 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.232 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.208 | Idelalisib | — uncovered |